This is a single-arm, exploratory clinical study.
Gender: no restriction; Age: 18-75 years.
Histologically or cytologically confirmed diagnosis of esophageal squamous cell carcinoma.
Clinical stage II-IVa (T2-4aN+M0) according to the AJCC 8th edition, and assessed as resectable by a multidisciplinary team (MDT).
Neck ultrasound and contrast-enhanced chest/abdominal CT.
Known history of hypersensitivity to macromolecular protein preparations. Contraindications or allergies to any component of epaplimut-pembrolizumab.
Other anti-tumor therapies (chemotherapy, radiotherapy, surgery, immunotherapy, biological therapy, chemoembolization, anti-tumor traditional Chinese herbal medicine).
Radiographic diagnosis indicating distant metastasis of the tumor.
History of allogeneic tissue/solid organ transplantation.
Single group
Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
DrugIparomlimab and Tuvonralimab: 5 mg/kg, Day 1; Lenvatinib: 8 mg, orally, once daily (QD), Day 1-14; Note: Lenvatinib will be discontinued starting from Cycle 3. Cisplatin: 75 mg/m², or Carboplatin: AUC 5, intravenously (IV), Day 1; Nab-paclitaxel: 125 mg/m², Day 1 and Day 8; The cycle repeats every 3 weeks.
Pathological Complete Response, pCR
objective response rate (ORR)
Major Pathologic Response（MPR）
In the tumor bed of the surgical resection specimen, necrotic or regressive tumor tissue ≥90 %.
Progression-Free Survival (PFS)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
